drugset / Trial / NCT06083662
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
NaSingle-groupOpen-labelTreatment
Summary
Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)
Timeline
- Start
- 2021-06-15
- Primary completion
- 2023-11-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 240 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |